Arthrosi Drug Trial in Gout Delivers for New Owner Sobi

Why It Matters

The data positions pozdeutinurad as a promising, better‑tolerated option for patients who fail existing gout therapies, potentially unlocking significant revenue for Sobi and reshaping the URAT1 inhibitor market.

Key Takeaways

• REDUCE-2 showed 69.2% achieved target uric acid at 75 mg dose
• Placebo response was only 8.1% achieving same uric acid target
• Sobi paid $950M upfront, $550M in milestones for Arthrosi acquisition
• URAT1 inhibitors face competition from newer agents like lingdolinurad and dotinurad

Pulse Analysis

Gout remains a high‑burden disease, affecting roughly 4% of U.S. adults and driving demand for therapies that can safely and consistently lower serum uric acid. Traditional uricosurics such as probenecid have limited efficacy and notable drug‑interaction risks, while newer agents like lesinurad have stumbled over safety concerns. Sobi’s strategic purchase of Arthrosi for $1.5 billion was a bet on a next‑generation URAT1 inhibitor that could overcome these hurdles, and the REDUCE‑2 results suggest the gamble may be paying off.

In REDUCE‑2, pozdeutinurad delivered a robust reduction in uric acid levels, with 69.2% of patients on the 75 mg dose reaching the therapeutic target of ≤6 mg/dl after six months—far outpacing the 8.1% placebo response. The drug’s oral, once‑daily dosing and favorable tolerability profile address two key shortcomings of prior URAT1 inhibitors, which suffered from complex regimens and renal safety warnings. If REDUCE‑1 confirms these findings, pozdeutinurad could become a first‑line option for patients whose gout remains uncontrolled on existing treatments.

Beyond pozdeutinurad, Sobi is expanding its gout franchise with NASP, a nano‑encapsulated sirolimus‑pegadricase combo, and is watching competitive pipelines from Atom Therapeutics and Fuji Yakuhin. The convergence of strong trial data, a sizable market, and unmet clinical need positions Sobi to capture a meaningful share of the projected $10 billion global gout‑therapy market. Successful regulatory approval could also accelerate milestone payments, further justifying the acquisition price and reinforcing Sobi’s growth trajectory in specialty pharmaceuticals.